Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent
Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find your favorite podcasts.
After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025.
The one for his contact lens maker with a history dating back to the 1800s.
"No, I doubt it [if we restart the deal process]," Saunders told me on Yahoo Finance's Opening Bid podcast (video above; listen in below). "You can never say never, but, look, we have a big ambitious plan for 2025, and frankly, as I look at 2026 and 2027, it's even a bolder plan. And so we're heads down and focused on operating the business and driving the best results we can."
Bausch and Lomb said earlier this month that it had explored taking the company private with a third-party buyer. No deal was reached, as a consortium of private equity firms including TPG (TPG) and Blackstone (BX) reportedly backed out. Bausch and Lomb said it would not pursue a transaction at this time.
But it reiterated a view a full separation from Bausch Health Companies is still the goal. Bausch Health Companies owns 88.4% of Bausch and Lomb.
Saunders believes interested buyers undervalued the company's product pipeline, which includes new technologies for contact lenses, dry eye relief, and surgical products.
"There's always skepticism in R&D, and I expect that. But, there was definitely a deeper discount ascribed to our R&D pipeline, whether it be in pharma or contact lenses or surgical, or even consumer," Saunders explained.
Saunders is known as one of the biggest dealmakers in the pharmaceutical industry of the past 15 years.
In May 2013, during his first run as the CEO of Bausch and Lomb, he orchestrated its $8.7 billion sale to Valeant Pharmaceuticals.
He then took over as the CEO of Forest Laboratories.
By February 2014, Saunders orchestrated the sale of the company to Actavis for $25 billion. He assumed the CEO position.
From there, in November 2014, he pulled off a $70 billion acquisition of Allergan and became its CEO.
That's where Saunders's star quickly rose in media circles, overseeing the commercial success of botox and battling with feared activist investor Carl Icahn.
Saunders then sold Allergan to Abbvie (ABBV) for $63 billion in a deal that closed in May 2020. He returned to Bausch and Lomb as CEO in March 2023.
Today, Icahn's son Brett sits on the Bausch and Lomb board along with hedge fund titan John Paulson and Saunders.
Bausch and Lomb's latest quarter underscored why Saunders is betting he could drive a higher valuation from a suitor later this year.
The company's fourth quarter sales rose 9% from the prior year to $1.28 billion. Analysts had expected $1.25 billion. Growth was driven by the company's vision care segment, where contact lens growth increased by 17% in the US and 11% internationally.
Adjusted earnings of $0.25 a share improved slightly year over year and beat Wall Street forecasts for $0.23 a share.
Watch: What Bill Gates sees as the future of healthcare
For the full year, Bausch and Lomb sees sales in a range of $4.95 billion to $5.05 billion. The Street was at $5.02 billion. The company forecast its dry-eye business to break $1 billion in sales this year, up from $916 million in 2024.
Added Saunders, "Our scientists in-house created a new material that we're going to drive into clinical trials this year and potentially launch in 2027 which could be a breakthrough — a biomimetic lens that really mimics the biology of your eye in a contact lens. We're hoping the clinical trials will prove it out that it's healthier for your eye, but it's also much more comfortable for your eye and really potentially an upgrade to the standard of care of contact lenses in just a couple years."
—
Three times each week, I field insight-filled conversations and chats with the biggest names in business and markets on Opening Bid. You can find more episodes on our video hub or watch on your preferred streaming service.
Brian Sozzi is Yahoo Finance's Executive Editor. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email brian.sozzi@yahoofinance.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
China's $1 Trillion Power Player Is Quietly Backing Out of Wall Street
China Investment Corporationthe $1.3 trillion heavyweight once courted by every major Wall Street firmis stepping back from the U.S. private asset scene. CIC recently pulled the plug on a proposed $1 billion sale of stakes in funds managed by KKR (NYSE:KKR), Carlyle (NASDAQ:CG), and TPG (NASDAQ:TPG), amid concerns it would amplify the optics of its broader U.S. retreat. Insiders say the fund was spooked by the political climate and the potential fallout from being perceived as bailing out of American private equity. While CIC attributes the decision to prudent risk management, the context suggests a deeper recalibration in response to mounting headwinds from both Washington and Beijing. Warning! GuruFocus has detected 4 Warning Signs with CG. This isn't just about one canceled sale. CIConce the savior of Morgan Stanley (NYSE:MS) during the 2008 crisis and an early backer of Blackstonehas been gradually throttling down its U.S. exposure for years. Alternative asset allocations fell below target in 2023. Compliance scrutiny has tightened. And CIC, once central to Wall Street's capital flows, now finds itself sidelined in co-investments and forced into sidecar vehicles to avoid regulatory tangles. New U.S. investment policies under Trump's America First agenda, along with plans to fast-track only friendly foreign investors, are making it harder for Chinese money to find a seat at the table. So where does CIC go next? The fund is doubling down on emerging markets, renewable energy, and dealmaking with Middle Eastern partners. It's still deploying capitalbut with less swagger than before. Internally, capital injections have slowed, talent has trickled out, and its global mandate has been diluted by rising domestic players like Central Huijin. For a fund born to project China's financial influence abroad, CIC is increasingly boxed incaught between politics, regulation, and a shrinking pool of strategic, high-return opportunities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Software group Visma picks London for IPO
Norwegian software group Visma has chosen London over Amsterdam for its upcoming initial public offering, marking a rare victory for the UK's struggling equity markets as it fights to remain relevant for high-growth tech listings. People familiar with the discussions told the Financial Times that London was ultimately selected because of the depth of its capital markets and a larger pool of investors focused on UK equities compared to those investing exclusively in Dutch stocks. Read more: London closes gap on New York as top global financial centre. The IPO, expected early next year, will test whether the UK government's recent efforts to revive London's capital markets are starting to bear fruit. The listing is contingent on implementing long-promised reforms, including measures that would allow companies listed in euros to be included in the FTSE indices, seen as critical for attracting European firms. Visma, which provides accounting, payroll and HR software across the Nordic, Benelux and Baltic regions, is valued at around €19bn (£16.2bn/$22.21bn). It is majority-owned by UK-based private equity firm Hg, which first invested in the company in 2006 and helped take it private from the Oslo stock exchange at a roughly $450m valuation. Hg and its co-investors currently hold approximately 70% of the company. The remainder is owned by minority shareholders, including Singapore's sovereign wealth fund GIC and US private equity firm TPG. The decision to list in London offers a glimmer of hope for the UK's primary markets, which have seen a sharp decline in new IPO activity. In 2023, 88 companies either delisted from the London Stock Exchange's main market or shifted their primary listing elsewhere, mainly to New York. Just 18 new listings took their place. So far, in 2025, only three IPOs have launched in the UK's primary market, raising less than £100m in total, according to LSE data. Read more: Arm chooses New York for key technology listing in 'kick in the teeth' for London At London Tech Week earlier this month, Bolt chief executive Markus Villig cast doubt on the capital's appeal. 'Let me look at the IPOs that have happened in the UK over the last five years,' he said. 'How many of them are left?' When British microchip company Arm decided to float in New York rather than London last year, experts called it a 'kick in the teeth' for London. "This is a blow to the UK government and the City of London post Brexit as Arm pins its hopes on New York, where some of the world's biggest tech companies have floated including Apple (AAPL) and Tesla (TSLA),' Victoria Scholar, head of investment at Interactive Investor, said at the time. 'Arm's abandonment of London is another kick in the teeth for the Square Mile's attractiveness among international investors as a go-to destination for technology giants", she added. Peter Harrison, head of the fund manager Schroders (SDR.L) and one of the City's most senior executives at the time also warned that the UK's failure to back 'risk takers' means London is unable to compete with New York. 'How do we create a system that is more willing to accept risk? Everything is about risk reduction. That has been the thing that has undermined growth, and importantly it has undermined returns [for investors],' he told Financial News. London Stock Exchange Group (LSEG.L) boss David Schwimmer said that, despite reforms to UK financial rules, there was no "silver bullet" to reverse the trend. Visma's listing could help shift that perception. Bank pitches for the IPO are expected to begin this in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
HPE CEO talks Nvidia AI partnership, IT spend, Juniper trial
Hewlett Packard Enterprise (HPE) is in the middle of its annual Discover event in Las Vegas to showcase its latest technological innovations. HPE CEO Antonio Neri sits down with Opening Bid host Brian Sozzi to explain how demand for networking and hybrid cloud remains solid, what IT spend looks like right now, and how the company is preparing for its upcoming Juniper acquisition trial with the US Department of Justice (DOJ). To watch more expert insights and analysis on the latest market action, check out more Opening Bid here. All right. For this, today's power player, I am locked in on Hewlett Packard Enterprises. Company is holding its annual Discover event in Vegas to show off its latest technologies to customers, especially on the AI front. HPE CEO Antonio Neri is here with me now from the event. Antonio, always great to see with see you. Don't know how you made time for me, but I appreciate it nonetheless. Out of all the announcements that you have come out with here, uh, from Discover, the announcement with Nvidia and AI factories really caught my attention. Why is that such a big thing for HPE's bottom line? Well, good morning, Brian, and thanks again for having me. What a great week for us here at HP Discover Vegas. I'm standing here on the show floor. It's a seven acres of technology on display. And after a great day yesterday at the sphere, where I gave my keynote. But to your point, yesterday we made a number of very strategic announcements. One of them, obviously, was the expansion of our AI factories with Nvidia. We continue to have a terrific partnership with Nvidia, expanding our solutions for sovereigns, which is an area where we see tremendous interest and growth. Obviously, the continued capex investment in service providers, as well as the continuation of the model builders. And then enterprise. And enterprise here, we have more than 12,000 customers visiting us this week. And they're all interesting to accelerate their journey to AI. And that tells you the interest is super, super high. And that's with Nvidia, we have co-architect, the co-engineered a solution that's easy to deploy it for time to value. Antonio, um, Keybank out with a good report here today. They surveyed a lot of CIOs who are out there buying tech. Um, they are noting the slowest IT spending growth outlook since 2020. How is that starting to take shape in your business? Well, look, we don't see a slowdown in IT spend. Uh, in fact, if you really follow the last few quarters of continuous revenue growth, you see that the momentum is across all line of businesses. Look, to deploy AI, continue your journey to a hybrid cloud experience across your enterprise, you need more networking. And so, networking has clearly recovered in the market. And we see that in our growth in our orders, and now in our revenue. Uh, GreenLake has been positioned extremely successful to be that bridge to provide a hybrid experience. And we continue to grow on an average of 35 to 45%. And this week, we announced the agentive approach to our GreenLake cloud. And what they're very interested is using GreenLake as an intelligence, meaning we can bring to them an army of AI agentive kind of capabilities, so they can remove people that are in the loop and put them on the loop. And so those actions can be taken by AI. So, I haven't seen that, honestly, Brian, but obviously there is a lot of uncertainty in the market. There's always geopolitical tension, but I think we'll continue to be a top of mind for enterprises. And Tony, before we let you go, and I know you're busy guy at this conference, um, July 9th is the Juniper trial. Would you assign any probability to this, I guess this trial not actually happening, that the government drops its case and lets you take battle versus Cisco in this market? Well, look, everything is possible. We continue to work to try to work a remediation sort of settlement, but fact of the matter is that we are so close to the trial. Our view is that we believe this is pro competitive, we believe this is good for enterprises. Remember, we don't support consumers. And ultimately, we believe we will prevail in court if we have to go all the way there. All right, we'll leave it there, Antonio Neri. Good to see you, as always. Good to see that HP stock symbol behind you at the conference. I'm digging it. Put something on black for me in Vegas. We'll talk to you soon. We'll do. Thank you.
